JPWO2021133866A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021133866A5 JPWO2021133866A5 JP2022539641A JP2022539641A JPWO2021133866A5 JP WO2021133866 A5 JPWO2021133866 A5 JP WO2021133866A5 JP 2022539641 A JP2022539641 A JP 2022539641A JP 2022539641 A JP2022539641 A JP 2022539641A JP WO2021133866 A5 JPWO2021133866 A5 JP WO2021133866A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- url
- retrieved
- vol
- internet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FARXPFGGGGLENU-UHFFFAOYSA-N 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Chemical compound C12=CC=3OCOC=3C=C2N(C)C=C1C1=C(C=2C3=CC(F)=CC=C3OC=2)C(=O)NC1=O FARXPFGGGGLENU-UHFFFAOYSA-N 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953654P | 2019-12-26 | 2019-12-26 | |
| US62/953,654 | 2019-12-26 | ||
| PCT/US2020/066762 WO2021133866A1 (en) | 2019-12-26 | 2020-12-23 | Compounds for the treatment of myelofibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508491A JP2023508491A (ja) | 2023-03-02 |
| JPWO2021133866A5 true JPWO2021133866A5 (https=) | 2023-12-26 |
| JP2023508491A5 JP2023508491A5 (https=) | 2023-12-26 |
Family
ID=74186982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539641A Pending JP2023508491A (ja) | 2019-12-26 | 2020-12-23 | 骨髄線維症の治療のための化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230062278A1 (https=) |
| EP (1) | EP4081213A1 (https=) |
| JP (1) | JP2023508491A (https=) |
| KR (1) | KR20230005808A (https=) |
| CN (1) | CN115697323A (https=) |
| AU (1) | AU2020415440A1 (https=) |
| BR (1) | BR112022012819A2 (https=) |
| CA (1) | CA3166251A1 (https=) |
| IL (1) | IL294369A (https=) |
| MX (1) | MX2022008046A (https=) |
| WO (1) | WO2021133866A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673368C (en) * | 2006-12-19 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| CN113384546A (zh) * | 2012-11-15 | 2021-09-14 | 因赛特公司 | 鲁索利替尼的缓释剂型 |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| CN106349224A (zh) * | 2016-08-03 | 2017-01-25 | 山东大学 | 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用 |
| WO2019222483A1 (en) * | 2018-05-17 | 2019-11-21 | Board Of Regents, The University Of Texas System | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
| CN112351819B (zh) * | 2018-06-05 | 2023-11-10 | 开动疗法公司 | 治疗恶性淋巴增生性疾病的方法 |
-
2020
- 2020-12-23 AU AU2020415440A patent/AU2020415440A1/en not_active Abandoned
- 2020-12-23 MX MX2022008046A patent/MX2022008046A/es unknown
- 2020-12-23 EP EP20842523.1A patent/EP4081213A1/en not_active Withdrawn
- 2020-12-23 US US17/789,321 patent/US20230062278A1/en not_active Abandoned
- 2020-12-23 BR BR112022012819A patent/BR112022012819A2/pt not_active Application Discontinuation
- 2020-12-23 WO PCT/US2020/066762 patent/WO2021133866A1/en not_active Ceased
- 2020-12-23 IL IL294369A patent/IL294369A/en unknown
- 2020-12-23 KR KR1020227025801A patent/KR20230005808A/ko not_active Withdrawn
- 2020-12-23 CN CN202080094791.2A patent/CN115697323A/zh active Pending
- 2020-12-23 CA CA3166251A patent/CA3166251A1/en active Pending
- 2020-12-23 JP JP2022539641A patent/JP2023508491A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021133866A5 (https=) | ||
| Turner et al. | Ecology of the Podocarpaceae in tropical forests | |
| Khan et al. | Aldosterone impairs coronary adenosine-mediated vasodilation via reduced functional expression of Ca2+-activated K+ channels | |
| Sasaki et al. | A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD | |
| Bowles et al. | Coronary smooth muscle adaptation to exercise: does it play a role in cardioprotection? | |
| Hofmann | Ido brings down the pressure in systemic inflammation | |
| Korovchinsky | A new species of the genus Diaphanosoma Fischer, 1850 (Crustacea: Cladocera: Sididae) from Japan | |
| Hsu et al. | Will we be singing a different tune on combined post-and pre-capillary pulmonary hypertension? | |
| Billingsley et al. | Fast Today, Feast Tomorrow: Can Intermittent Fasting Improve Right Ventricular Function in Pulmonary Arterial Hypertension? | |
| Chan et al. | Protective effects of histamine on Gq-mediated relaxation in regenerated endothelium | |
| Lieberman | Further fossil finds from Flores | |
| Stramucci et al. | Twisting IL-1 signaling to kill CML stem cells | |
| Vogel | Binge drinking and vascular function: a sober look at the data | |
| Nyende | Jesus, the greatest ancestor: a typology-based theological interpretation of Hebrews' Christology in Africa | |
| Humphreys et al. | Abstract C10: A novel combination of a small molecule IAP inhibitor and a TRAIL‐R1 monoclonal antibody synergize to induce apoptosis in pancreatic tumor cell lines | |
| Soldati | Some Remarks about Coptic Colophons and Their Relationship with Manuscripts: Typology, Function, and Structure | |
| Hicks | Correction: Corrigendum: Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis | |
| Попель-Махницки et al. | The Motif of Human Confrontation With COVID-19 in the Latest Poems by Alexander Gorodnitsky, Dmitry Bykov, and Dmitry Danilov | |
| KHAYAT et al. | The effect of ketoconazol chronic administration on histomorphometric changes of testicular tissue in mice | |
| Koepl et al. | Abstract# 2114: Polymorphisms in 5-lipoxygenase-activating protein and risk of colon cancer | |
| Wicker et al. | Glutaminase inhibition in combination with ionizing radiation improves treatment response in head and neck squamous cell carcinoma models | |
| Westerink | Niki Kasumi Clements, Sites of the Ascetic Self: John Cassian and Christian Ethical Formation (Notre Dame, University of Note Dame Press, 2020), ISBN 9780268107857; xi+ 280 pp., $65, 00 (hardcover). | |
| Sivaramakrishnan et al. | Binding to a novel RNA-protein complex creates specificity for small molecule splicing modifiers to treat SMA | |
| Merculio | Assessment of the influence of the body condition score of water buffaloes (Bubalus bubalis) on the physiological state and quality of oocytes of ovaries | |
| Mathai | The influence of exhaustive exercise and glycogen repletion on the expression of PGC-1alpha in human skeletal muscle. |